Literature DB >> 1701124

Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status.

D R Clemmons1, C Camacho-Hubner, E Coronado, C K Osborne.   

Abstract

Breast tumor cell lines have been shown to secrete several distinct polypeptide growth factors, although conflicting results exist for the insulin-like growth factors (IGFs). In contrast a limited number of breast tumor cell lines have definitely been shown to secrete the high affinity IGF binding proteins (IGFBPs) that modify IGF actions. To characterize the types of IGFBPs that are secreted by breast tumor cell lines, conditioned medium was collected from seven separate tumor cell lines, three of which were estrogen receptor (ER) negative, and four of which were ER positive. All three of the ER negative cell lines, MDA-231, MDA-330, and HS578T, secreted binding proteins of 49,000 and 43,000 Mr (IGFBP-3) as well as 29,000 (IGFBP-1) and 24,000 Mr. In contrast, all four ER positive cell lines secreted 34,000 (IGFBP-2) or 24,000 Mr forms, and none secreted the 49,000 and 43,000 or 29,000 Mr forms. BT-20, a cell line that is positive for ER messenger RNA (mRNA) but negative for ER protein, secreted predominantly a 34,000 Mr protein. The amount of total IGFBP activity released in 24 h ranged between 0.4 and 5.6 nM equivalents of IGFBP-1, and there was no significant difference between the ER positive and negative cell lines. The MCF-7 cells that produced predominantly 34,000 and 24,000 Mr forms showed a 1.8-fold increase in IGFBP secretion after estrogen stimulation. Immunoblotting and a specific RIA for IGFBP-1 showed that only the ER negative lines MDA-330, MDA-231, and HS578T secreted this form. Northern blotting analysis for the mRNA encoding this protein showed that both MDA-330 and MDA-231 contained a single 1.6 kilobase mRNA species that hybridized with an IGFBP-1 complementary DNA (cDNA) probe. Immunoblotting analysis of the other cell lines showed that only the 34,000 Mr form secreted by the ER positive cell lines reacted with IGFBP-2 antisera. Exposure of the conditioned media from the three ER negative cell lines to N-glycanase revealed that the 49,000 and 43,000 Mr forms of IGFBP were glycosylated and therefore probably represent IGFBP-3. We conclude that ER negative cell lines secrete three forms of IGFBPs, IGFBP-1, IGFBP-3, and a 24,000 Mr form. In contrast, the ER positive cell lines secrete predominantly IGFBP-2 and the 24,000 Mr form but do not secrete IGFBP-3 or 1.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1701124     DOI: 10.1210/endo-127-6-2679

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  23 in total

Review 1.  Insulin-like growth factor binding proteins (IGFBPs) in breast cancer.

Authors:  C M Perks; J M Holly
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-01       Impact factor: 2.673

Review 2.  The role of circulating IGF-I: lessons from human and animal models.

Authors:  Shoshana Yakar; Yiping Wu; Jennifer Setser; Clifford J Rosen
Journal:  Endocrine       Date:  2002-12       Impact factor: 3.633

Review 3.  The insulin-like growth factor binding proteins (IGFBPs) in human breast cancer.

Authors:  J A Figueroa; D Yee
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 4.  Regulation of insulin-like growth factors by antiestrogen.

Authors:  R Winston; P C Kao; D T Kiang
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 5.  Insulin-like growth factors in central nervous system tumors.

Authors:  R P Glick; T Lichtor; T G Unterman
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

6.  Simultaneous expression of nitric oxide synthase and estrogen receptor in human breast cancer cell lines.

Authors:  R Zeillinger; E Tantscher; C Schneeberger; W Tschugguel; S Eder; G Sliutz; J C Huber
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

7.  Significant expression of IGFBP2 in breast cancer compared with benign lesions.

Authors:  L-T Busund; E Richardsen; R Busund; T Ukkonen; T Bjørnsen; C Busch; H Stalsberg
Journal:  J Clin Pathol       Date:  2005-04       Impact factor: 3.411

8.  Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells.

Authors:  R R Perry; Y Kang; B Greaves
Journal:  Ann Surg Oncol       Date:  1995-05       Impact factor: 5.344

9.  Insulin-like growth factor-I (IGF-I) and IGF-binding proteins blood serum levels in women with early- and late-stage breast cancer: mutual relationship and possible correlations with patients' hormonal status.

Authors:  R E Favoni; A de Cupis; A Perrotta; S Sforzini; D Amoroso; F Pensa; L Miglietta
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

10.  Protein expression pattern in response to ionizing radiation in MCF-7 human breast cancer cells.

Authors:  Samil Jung; Soonduck Lee; Jayhee Lee; Chengping Li; Ji-Yeon Ohk; Hyeon-Kyung Jeong; Seungkyu Lee; Sangwoo Kim; Yunyeong Choi; Sunghak Kim; Heungwoo Lee; Myeong-Sok Lee
Journal:  Oncol Lett       Date:  2011-10-18       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.